Indevus completes enrollment in second phase 3 trial for Sanctura XR

By Elaine Rigoli

Tampa, Fla., March 21 - Indevus Pharmaceuticals, Inc. reported that enrollment has been completed in the company's second phase 3 trial for Sanctura XR, a once-daily formulation of Sanctura, which is marketed for overactive bladder.

The second of the two phase 3 trials is fully enrolled with more than 560 patients, and the company anticipates reporting results in July, according to a news release.

Earlier this month, the company reported the completion of enrollment in the first of its two phase 3 trials.

Both trials are 12-week, double-blind, placebo-controlled studies evaluating the effect of Sanctura XR in reducing frequency, urgency and incontinence episodes in patients with overactive bladder.

Lexington, Mass.-based Indevus is a biopharmaceutical company that develops products targeting certain medical specialty areas, including urology, gynecology and men's health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.